Wellbutrin XL is an Extended-Release Formulation
Yes, Wellbutrin XL is an extended-release (XL) formulation of bupropion that is administered once daily. This is distinct from Wellbutrin SR (sustained-release), which requires twice-daily dosing, and the immediate-release formulation, which requires three-times-daily dosing 1.
Formulation Details
The FDA drug label clearly specifies that Wellbutrin XL is designed for once-daily administration in the morning 1. The extended-release technology allows for:
- Single daily dosing (typically in the morning)
- Doses of 150 mg or 300 mg as extended-release tablets
- Tablets must be swallowed whole and cannot be crushed, divided, or chewed, as this would alter the release rate 1
Comparison with Other Bupropion Formulations
Multiple guidelines and the FDA label distinguish three bupropion formulations 2, 3:
- Immediate-release (IR): Three times daily dosing
- Sustained-release (SR): Twice daily dosing (e.g., 150 mg BID)
- Extended-release (XL): Once daily dosing (e.g., 150-300 mg daily)
All three formulations are bioequivalent in terms of systemic exposure to bupropion 4, but the XL formulation provides the convenience of once-daily dosing with a lower peak concentration (Cmax) and longer time to peak compared to SR 5.
Clinical Implications
The extended-release nature of Wellbutrin XL means:
- Patients should take it once daily in the morning to minimize insomnia risk
- If a dose is missed, patients should not double up due to seizure risk 1
- The tablet integrity must be maintained (no crushing/splitting) to preserve the extended-release mechanism
- When discontinuing 300 mg daily, taper to 150 mg daily first before stopping 1
The XL formulation has demonstrated similar effectiveness to SR formulation for both depression treatment 6, 4 and smoking cessation 7, with the advantage of simplified once-daily dosing that may improve adherence.